News coverage about Achaogen (NASDAQ:AKAO) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Achaogen earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 45.2462914845717 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Here are some of the news stories that may have effected Accern Sentiment’s rankings:

How to Become a New Pot Stock Millionaire

AKAO has been the subject of a number of analyst reports. William Blair reaffirmed an “outperform” rating on shares of Achaogen in a report on Wednesday, February 28th. ValuEngine raised shares of Achaogen from a “sell” rating to a “hold” rating in a report on Monday, April 2nd. Zacks Investment Research downgraded shares of Achaogen from a “hold” rating to a “sell” rating in a report on Wednesday, February 14th. Needham & Company LLC reiterated a “buy” rating and set a $20.00 target price (down previously from $29.00) on shares of Achaogen in a research report on Wednesday, February 28th. Finally, Leerink Swann reiterated an “outperform” rating on shares of Achaogen in a research report on Sunday, March 4th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $23.56.

AKAO traded up $0.23 during midday trading on Tuesday, hitting $12.44. The company had a trading volume of 400,743 shares, compared to its average volume of 1,221,912. The company has a current ratio of 4.83, a quick ratio of 4.83 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $554.15, a PE ratio of -3.92 and a beta of 1.02. Achaogen has a twelve month low of $9.83 and a twelve month high of $27.49.

Achaogen (NASDAQ:AKAO) last posted its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.21). The company had revenue of $1.87 million during the quarter, compared to analyst estimates of $1.18 million. Achaogen had a negative net margin of 1,124.10% and a negative return on equity of 83.14%. research analysts predict that Achaogen will post -3.47 EPS for the current year.

In other news, insider Kenneth J. Hillan sold 4,606 shares of Achaogen stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $10.67, for a total transaction of $49,146.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Robert W. Duggan purchased 527,396 shares of the stock in a transaction dated Friday, March 2nd. The shares were acquired at an average price of $10.31 per share, with a total value of $5,437,452.76. Following the transaction, the insider now owns 5,697,752 shares in the company, valued at $58,743,823.12. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 810,717 shares of company stock valued at $8,739,717 and sold 10,089 shares valued at $110,576. Company insiders own 8.36% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at

Achaogen Company Profile

Achaogen, Inc, a late-stage biopharmaceutical company, focusses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.

Insider Buying and Selling by Quarter for Achaogen (NASDAQ:AKAO)

Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with's FREE daily email newsletter.